NCT06249152View on ClinicalTrials.gov

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 21, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions
Open-angle Glaucoma (OAG)Ocular Hypertension (OHT)Glaucoma
Interventions
DRUG

QLS-111, 0.015%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111, 0.030%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111, 0.075%

QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

DRUG

QLS-111 vehicle ophthalmic solution

Vehicle drops applied QPM for 14 days the BID for 14 days.

Trial Locations (1)

77027

Berkeley Eye Center, Houston

All Listed Sponsors
lead

Qlaris Bio, Inc.

INDUSTRY

NCT06249152 - Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients | Biotech Hunter | Biotech Hunter